Metal compounds mixed or sulphated, as phosphate binders
A mixed metal compound for pharmaceutical use is free from aluminum and has a phosphate binding capacity of at least 30%, by weight of the total weight of phosphate present, over a pH range of from 2-8. The compound is especially useful for treatment of hyperphosphataemia. The metals are preferably iron (III) and at least one of calcium, magnesium, lanthanum and cerium. A metal sulphate for pharmaceutical use is selected from at least one of calcium, lanthanum and cerium sulphate compounds and has a phosphate binding capacity of at least 30% by weight of the total phosphate present, over a pH range from 2-8.
1. An oral pharmaceutical preparation comprising a pharmaceutically acceptable phosphate-binding, inorganic mixed metal compound, wherein said compound is free from aluminum and contains iron (III), and at least one additional metal M selected from the group consisting of magnesium, calcium, lanthanum and cerium, wherein the pharmaceutical preparation comprises a therapeutically effective amount of the mixed metal compound effective in controlling serum phosphate levels in patients suffering from or predisposed to hyperphosphatemia.
2. The oral pharmaceutical preparation of claim 1 , wherein the ratio M:Fe in the compound is at least 1.7:1.
3. The oral pharmaceutical preparation of claim 1 , wherein the ratio M:Fe in the compound is up to 5:1.
4. The oral pharmaceutical preparation of claim 1 , wherein the ratio or M:Fe in the compound is 2:1.
5. The oral pharmaceutical preparation of claim 1 , wherein the additional metal comprises calcium.
6. The oral pharmaceutical preparation of claim 1 , wherein the additional metal comprises magnesium.
7. The oral pharmaceutical preparation of claim 1 , wherein the compound additionally contains at least one ion selected from the group consisting of sulphate, chloride, oxide, and mixtures thereof.
8. The pharmaceutical oral preparation of claim 1 , wherein the compound contains hydroxyl and/or carbonate ions.
9. The pharmaceutical oral preparation of claim 8 , wherein the compound contains hydroxyl and carbonate ions.
10. The pharmaceutical oral preparation of claim 1 , wherein the compound has a hydrotalcite type structure.
11. The pharmaceutical oral preparation of claim 1 , wherein the mixed metal compound is unaged.
12. A pharmaceutical oral preparation comprising a pharmaceutically acceptable phosphate-binding, inorganic mixed metal compound, wherein said compound is free from aluminum and contains iron (III), and at least one additional metal M selected from the group consisting of magnesium, calcium, lanthanum and cerium, wherein the mixed metal compound is dry and ground, and wherein the pharmaceutical preparation comprises a therapeutically effective amount of the mixed metal compound effective in controlling serum phosphate levels in patients suffering from or predisposed to hyperphosphatemia.
13. The pharmaceutical oral preparation of claim 12 , wherein the mixed metal compound is a dry powder.
14. The pharmaceutical oral preparation of claim 12 , wherein the compound contains hydroxyl and carbonate ions.
15. The pharmaceutical oral preparation of claim 12 , wherein the additional metal comprises magnesium.
16. A pharmaceutical oral preparation comprising a pharmaceutically acceptable phosphate-binding, inorganic mixed metal compound, wherein said compound is free from aluminum and contains iron (III), and at least one additional metal M selected from the group consisting of magnesium, calcium, lanthanum and cerium, wherein the pharmaceutical preparation comprises a therapeutically effective amount of the mixed metal compound effective in controlling serum phosphate levels in patients suffering from or predisposed to hyperphosphatemia, and wherein the compound is effective for binding at least 30% by weight of the total phosphate present, as measured by any of the following methods (1) or (2), over a pH range of 3 to 7:
(1) adding 1 gram of the mixed metal compound to 25 ml of 40 mmol l −1 sodium phosphate buffer solution, homogenizing and gently agitating at room temperature for 30 minutes, centrifuging at 3000 rpm for 5 minutes, filtering through 0.22 μm Millipore filter and measuring the soluble phosphate in the supernatant thus produced;
(2) adding 1 gram of the mixed metal compound to 25 ml of 20 mmol l −1 sodium phosphate buffer solution, homogenizing and gently agitating at room temperature for 30 minutes, centrifuging at 3000 rpm for 5 minutes, filtering through 0.22 μm Millipore filter and measuring the soluble phosphate in the supernatant thus produced.
17. The pharmaceutical oral preparation of claim 16 , wherein the compound has a phosphate binding capacity of at least 30% by weight over a pH range of 2 to 8.
18. The pharmaceutical oral preparation of claim 16 , wherein the compound contains hydroxyl and carbonate ions.
19. The pharmaceutical oral preparation of claim 16 , wherein the additional metal comprises magnesium.
20. The pharmaceutical preparation of claim 16 , wherein the mixed metal compound is dry and ground.